コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 tients (147 CMV disease and 135 asymptomatic viremia).
2 pithelial cells in the absence of detectable viremia.
3 a prolonged period of intermittent low-level viremia.
4 h an epidemic ZIKV, and completely prevented viremia.
5 IRF4(hi) subsets than did animals with high viremia.
6 eactive airway disease than patients without viremia.
7 ient developed CMV-T cell responses post-CMV viremia.
8 experienced full suppression of HIV-1 plasma viremia.
9 ues, especially in the setting of persisting viremia.
10 in the mesenteric lymph node correlated with viremia.
11 ficantly with incidence of posttransplant BK viremia.
12 ) were more likely to develop persistent EBV viremia.
13 ion of immune suppression at the onset of BK viremia.
14 between macaques that exhibited high or low viremia.
15 to screen individuals on ART for detectable viremia.
16 ficant subset of patients may have recurrent viremia.
17 patients with SVRs, but not in patients with viremia.
18 tomegalovirus and BK and 2 others EBV and BK viremia.
19 mablast frequency negatively correlated with viremia.
20 , which may be driven partly by maternal HIV viremia.
21 of minimizing immunosuppression to treat BK viremia.
22 the source of virus resulting in viruria and viremia.
23 igh viremia, but not in those with very high viremia.
24 infection when administered at the onset of viremia.
25 positively correlated with decreased plasma viremia.
26 ) do not develop AIDS despite high levels of viremia.
27 V-infected macaques contribute to control of viremia.
28 rals in compensated cirrhosis with low-level viremia.
29 ers did not recover after resolution of peak viremia.
30 documented HHV-6 reactivation and persistent viremia.
31 positively with both acute-phase and chronic viremia.
32 l immunosuppression that contributes to high viremia.
33 rvix were negatively correlated with chronic viremia.
34 postpartum than women who failed to control viremia.
35 of the clinical manifestations or on dengue viremia.
36 which can predict risk of progression to CMV viremia.
37 urines from patients without concomitant BK-viremia.
38 population less efficient in controlling HIV viremia.
39 were prospectively monitored for subsequent viremia.
40 all signs of Ebola virus disease, including viremia.
41 loss of these responses eventually leads to viremia.
42 y appears to achieve complete suppression of viremia.
43 e earlier than in the group with viruria and viremia.
44 y" cells, and/or significant polyomavirus BK viremia.
45 ne in response to chronic Epstein-Barr virus viremia.
46 r HIV subjects with undetectable HCMV plasma viremia.
47 lly HIV-infected individuals with detectable viremia.
48 ad 10-year outcomes similar to those without viremia.
49 tinfection and if this translated to reduced viremia.
50 with patients with prolonged episodes of BK viremia.
51 rugs that are used in combination to control viremia.
52 ember 2013; 32 (32%) tested positive for CMV viremia.
53 Of these 12 patients with late recurrent viremia, 11 had the same HCV genotype/subtype at baselin
55 (cystitis) (34.9% vs 25.2%), cytomegalovirus viremia (17.8% vs 24.2%), flu-like syndrome (11.6% vs 14
56 nput cells/mouse) experienced very low level viremia (201 copies/mL); sequence confirmation was unsuc
58 4+ T cells from PrEP Participant B developed viremia (50 million input cells/surviving mouse), but on
59 like syndrome (11.6% vs 14.1%), polyoma (BK) viremia (8.2% vs 11.1%), and herpes simplex infections (
62 ntiretroviral therapy (ART) can fuel rebound viremia after ART interruption and is a central obstacle
64 nd nonhuman primates, and protection against viremia after ZIKV challenge correlated with serum neutr
65 ed by protective HLA alleles, but control of viremia also occurs in the presence of selected CTL esca
66 ve and specific method for monitoring plasma viremia among adults and children on ART at the WHO-reco
71 though previous studies have implicated high viremia and associated immune activation as potential dr
72 omarkers were evaluated for correlation with viremia and clinical disease in an effort to identify pa
73 s study, we sought to compare the quantified viremia and clinical presentation of patients infected w
75 st was used to compare the proportion of CMV viremia and CMV retinitis in patients transplanted betwe
76 viral entry, and treatment with 25HC reduced viremia and conferred protection against ZIKV in mice an
79 idians bacteremia, and cytomegalovirus (CMV) viremia and identified mutations in 2 genes that regulat
80 8 levels were correlated with detectable HIV viremia and inversely with CD4 count (p<0.0001), consist
82 14 postinfection had a significant effect on viremia and mortality, resulting in 100% survival of inf
84 ples from four HIV-infected donors (one with viremia and not on ART and three with viremia suppressed
85 sons, active HIV replication correlated with viremia and occurred in CD4 T cells expressing T follicu
86 mera-infected marmosets exhibited consistent viremia and one showed transient viremia during the cour
87 The ability of IFN-alpha14 to reduce both viremia and proviral loads in vivo suggests that it has
88 erapy allows macaques to effectively control viremia and reconstitute their immune systems without a
90 indirect effects of CMV, possible impact of viremia and risk factors for CMV infection in pediatric
94 ody correlated temporally with resolution of viremia and termination of virus shedding in oropharynge
95 e multicenter data comparing the kinetics of viremia and toxicities following preemptive treatment wi
96 frequency positively correlated with plasma viremia and unvaccinated macaques had increased plasma c
97 ighly sensitive and specific, but periods of viremia and viruria are brief, limiting the utility of Z
99 test was only seen in some patients with BK viremia and was not associated with hemorrhagic cystitis
100 RV-C infections were highly associated with viremia and were usually the only respiratory pathogen i
101 need to improve methods used to monitor HDV viremia and will be instrumental in achieving that goal.
103 ingly contradictory observations on residual viremia and, with relatively few parameters, recapitulat
107 lay between HBV serological status, level of viremia, and the immunosuppressive potency of the drug(s
108 lted in increased morbidity-including fever, viremia, and viral loads in spinal cord and testes-and i
109 s was consistently observed, with occasional viremia, and virus was isolated from tonsils, gut mucosa
112 73 ECs, 42 with pharmacologically suppressed viremia (ART), 42 with uncontrolled viral replication (n
114 of the NHP species studied, the magnitude of viremia, as measured by area under the curve, during the
115 cleared were among the 15 with undetectable viremia at 12 months, making that time point a strong pr
116 te-phase production of MCP-1 correlated with viremia at 3 months postinfection in both nonprogressive
119 ollers have the striking ability to maintain viremia at extremely low or undetectable levels without
120 Background: HIV-1-controllers maintain HIV-1 viremia at low levels (normally <2000 HIV-RNA copies/mL)
124 to achieve SVR in patients with undetectable viremia at week 1, but would be suboptimal in general.
127 specific reduction of MoMLV cell-free plasma viremia but not the number of infected hematopoietic cel
130 of macaques with a high ZIKV dose results in viremia, but that transmission risk from saliva of infec
134 5 transplant recipients with and without CMV viremia by using a microarray chip covering 847 hsa-miRN
135 There is concern that even low levels of viremia can result in CZS, meaning an effective vaccine
136 retroviral therapy (ART) correlated with HIV viremia, CD4(+) T-cell counts, and immune activation mar
137 ow a reduction in the number of days of ZIKV viremia compared to naive macaques and that the previous
140 NKG2D, and IL-18Ralpha were associated with viremia control, as was Ab-dependent cytotoxic function.
141 (all VL results <200 copies/mL) and examined viremia copy-years and time spent above VL levels that i
142 to build the following cumulative measures: viremia copy-years, CD4-years, and VACS Index score-year
143 ed horses became viremic after 1 or 2 wk and viremia could be detected in two horses for several week
144 as an avidity index of <30%, followed by HCV viremia detection) had an MDRI of 147 days (95% confiden
146 drug resistance should be suspected when CMV viremia (DNAemia or antigenemia) fails to improve or con
147 virus that was detected as persistent plasma viremia during cART in an HIV-1-infected patient who had
149 e 669 patients (58%) had at least 1 positive viremia during follow-up.Epstein-Barr virus D+/R- patien
152 g a second agent in patients with persistent viremia during treatment, and the effectiveness of antiv
159 s in tonsils and Peyer's patches (explaining viremia), extending previous studies of poliovirus patho
160 cinated sheep, as evidenced by prevention of viremia, fever and absence of RVFV-associated histopatho
166 first episode of CMV disease or asymptomatic viremia (>/=1000 IU/mL) requiring treatment were identif
167 ndergoing immunosuppression reduction for BK viremia had 10-year outcomes similar to those without vi
169 oth patients with either HBsAg positivity or viremia had recurrent hepatocellular carcinoma diagnosed
170 The remaining 5 patients with late recurrent viremia had virologic relapse in which the HCV present a
171 ng strain had a lower risk of developing BKV viremia (hazard ratio [HR], 0.44; 95% confidence interva
172 us, despite their partial ability to control viremia, HIV-specific CD8(+)T cell responses are insuffi
176 (+) lymphocytes resulted in increased plasma viremia in all animals and that repopulation of CD8(+) T
177 rhesus macaques results in detectable plasma viremia in all animals by 2 days post-exposure; virus re
183 accine to prevent or significantly attenuate viremia in pregnant women who are residents of or travel
186 neutralizers typically are unable to reduce viremia in the same individuals from whom they are isola
187 lization in vitro and a moderate decrease of viremia in vivo IMPORTANCE: Antibodies can protect from
188 avel-related exposures, a vaccine to prevent viremia in women of childbearing age and their partners
189 1 infection to undetectable levels of plasma viremia, integrated latent HIV-1 genomes that encode rep
191 ity, the detection window of RT-PCR for Zika viremia is only about one week after symptom onset.
193 L; P = .01), a 0.76 log10 lower longitudinal viremia level (P = .01), and slower progression to a CD4
194 the time to CD4(+) T-cell count decline and viremia level after infection and the potential for vacc
195 n a novel lethal mouse model, it lowered the viremia level and the virus load in organs and normalize
196 In contrast to prior reports, the persistent viremia level continues to slowly decline during years 4
197 , commenced 4 days after infection, when the viremia level had reached 4 log10 virus particles/mL, re
199 rated genome-wide genotype, gene expression, viremia level, and weight gain data to identify genetic
200 %-69% and 90%-84% of cases, respectively, as viremia levels declined, while anti-DENV IgM ELISA detec
201 long-lived humoral immune responses, despite viremia levels of up to 6.44 log10 copies per mL of seru
202 ssion of GBP5, GBP6, CCHCR1 and CMPK2 affect viremia levels or weight gain in response to PRRSV infec
204 ing HIV prevalence and the prevalence of HIV viremia (linear regression coefficient per 1-percentage-
205 onstructural protein 1 (NS1) rapid test, and viremia magnitude were all independently associated with
206 ry pathogen identified, suggesting that RV-C viremia may be an important diagnostic indicator in pedi
208 here monocytes/macrophages contribute to CNS viremia, neuroinflammation, and increased mortality.
209 t allogeneic HSCT; 13 patients (46%) had CMV viremia, not a statistically significant increase (P = .
212 zing serostatus had the greatest risk for BK viremia (odds ratio, 4.9; 95% confidence interval, 1.7-1
213 led for the disease with a consistent plasma viremia of <200 copies/mL (mean CD4(+)-cell count, 475.1
214 ally infected untreated subjects with plasma viremia of <3,000 RNA copies/ml over 17 to 179 weeks.
215 ollers, defined as those with episodes of BK viremia of 3 months or less, had an 11-fold increase in
216 into rhesus monkeys did not result in either viremia or apparent clinical symptoms, although DTMUV-sp
217 The primary outcome was recurrence of CMV viremia or disease within 6 months of treatment disconti
219 blood samples obtained from individuals with viremia or individuals on long-term suppressive antiretr
220 The effect of polyomavirus reactivation (BK viremia or JC viruria) on antibodies to kidney-specific
221 t risk factor for posttransplant viruria and viremia (OR, 4.52; CI, 2.33-8.77; P < 0.0001) and nephro
222 tly elevated in individuals with high plasma viremia (P < 0.0001) and are positively correlated with
226 nvestigated the prevalence of late recurrent viremia (patients with sustained virologic response 12 w
227 nce interval, 1.88-157.87; P = 0.012), while viremia per se did not worsen LT outcomes, such as the i
229 infected animals with persistent circulating viremia presented characteristics typical of viral hepat
230 epositories for having varying degrees of BK viremia (range, 0-1.0 x 10 copies/mL), hemorrhagic cysti
232 15.2%-64.6%), significantly higher than the viremia rate of 0.93% (95% CI, .11%-3.34%) in nonexposed
233 d suppression of viral replication with ART, viremia rebounds rapidly after treatment interruption.
235 s of HBV-specific T cells caused progressive viremia reduction within 12 days of treatment in animals
236 detection rate of HIV-infected persons with viremia (regardless of their awareness status) was 0.7 p
237 izing activity (D+) had elevated risk for BK viremia, regardless of recipient serostatus (D+ versus D
238 with haplotype-matched hepatocytes, whereas viremia remained stable in mice receiving irrelevant T c
239 g therapy or those who spontaneously control viremia remains an obstacle to definitive treatment.
240 s were detected in levels of residual plasma viremia, replication-competent reservoirs, proviral DNA,
242 ne responses correlated with the kinetics of viremia resolution, the CD8 T-cell response was of surpr
244 ibody and T-cell response to HCV NS3 in this viremia-resolved marmoset was boosted by rechallenging,
246 ation led to HIV-1 reservoir reduction after viremia resuppression, as indicated by the quantity of H
249 cipient serostatus and the development of BK viremia, specific risk factors for BKV-related complicat
250 inal fluid for months after the clearance of viremia suggest the ability of ZIKV to establish persist
251 e with viremia and not on ART and three with viremia suppressed on ART) revealed that an average of 7
253 teen and thirty months, respectively, before viremia suppression, and served as positive controls for
255 all patients, hospitalized cases had higher viremia than those who did not require hospitalization (
257 nd implement screening measures for AIV H5N1 viremia that allows for rapid response to this potential
258 ads to a significant enhancement of Dengue-2 viremia that is accompanied by neutropenia, lympocytosis
260 s in tonsils and Peyer's patches (explaining viremia), thereby supplementing historical reconstructio
263 iretroviral therapy (cART) suppresses plasma viremia to undetectable levels that rebound upon cART tr
264 s was consistently observed, with occasional viremia; tonsil, mesentery lymph nodes, and intestinal m
266 men enrolled in U.S. cohort studies for HEV viremia using a high-throughput nucleic acid testing (NA
267 from FMD clinical signs and did not develop viremia, virus shedding or antibodies against FMDV nonst
268 type I IFN receptor in mice caused apparent viremia, viscerotropic disease, and mortality, indicatin
271 Of 39 134 recruited blood donors, DENV-4 viremia was confirmed in 0.51% of donations from subject
279 than controls, but a trend for higher acute viremia was observed in the DM+VLP group, likely due to
280 and soluble CD40 ligand (sCD40L) and chronic viremia was observed only for the nonprogressive infecti
282 Remarkably, the incidence of posttransplant viremia was reduced among cases with high pretransplant
284 both comparisons), and for each virus, mean viremia was significantly lower in coinfections than in
285 y (ART)-naive individuals were enrolled, and viremia was suppressed by ART prior to delivery of 4 dos
290 enotype and 12-month postpartum undetectable viremia were the best predictors for viral decline and s
292 previously exposed to DENV exhibited higher viremia when exposed to a subsequent, heterologous dengu
293 munized animals had significantly lower peak viremia which inversely correlated with prechallenge SIV
294 l, could be detected early after start of BK viremia, which would provide insight into the mechanism
295 ot observed in every patient with detectable viremia who received preemptive antiviral therapy, sugge
298 STATEMENT Despite successful suppression of viremia with increased longevity in the era of combined
300 y transmit for months after the clearance of viremia, ZIKV must establish infection in the seminifero
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。